LIXTE Biotech Updates Principal Executive Offices
Ticker: LIXT · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1335105
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative-change
TL;DR
**LIXTE Biotech moved its main office, signaling potential operational changes.**
AI Summary
LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K on January 30, 2024, reporting an event on January 29, 2024, to update its principal executive offices to 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101. This change matters to investors because it indicates a potential operational shift or expansion, which could impact the company's efficiency and future growth prospects, ultimately affecting stock valuation.
Why It Matters
This filing signals a change in the company's operational base, which could reflect strategic decisions impacting its future efficiency and growth potential.
Risk Assessment
Risk Level: low — A change in business address is generally a low-risk event, as it doesn't directly impact financial performance or core operations.
Analyst Insight
Investors should monitor future filings for any strategic announcements or operational changes that might be linked to this relocation, as a change in address alone is not a significant catalyst.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — the registrant filing the 8-K
- January 29, 2024 (date) — date of earliest event reported
- January 30, 2024 (date) — date of filing
- 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 (address) — new principal executive offices
- 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 (address) — previous business address
Forward-Looking Statements
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. will experience minor operational disruptions due to the office relocation. (LIXTE BIOTECHNOLOGY HOLDINGS, INC.) — low confidence, target: 2024-03-31
- The change of address may precede an announcement of new strategic partnerships or initiatives in the Pasadena area. (LIXTE BIOTECHNOLOGY HOLDINGS, INC.) — low confidence, target: 2024-06-30
FAQ
What was the specific event reported in this 8-K filing by LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
The specific event reported was a change in the company's principal executive offices, effective January 29, 2024.
What is the new address for LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s principal executive offices?
The new address for LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s principal executive offices is 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on January 30, 2024.
What is the trading symbol for LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Common Stock and where is it registered?
The trading symbol for LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Common Stock is LIXT, and it is registered on The Nasdaq Stock Market LLC.
What is the company's telephone number listed in the filing?
The company's telephone number listed in the filing is (631) 830-7092.
Filing Stats: 374 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-01-29 19:28:20
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001493152-24-004201.txt ( ) — 275KB
- lixt-20240129.xsd (EX-101.SCH) — 3KB
- lixt-20240129_def.xml (EX-101.DEF) — 26KB
- lixt-20240129_lab.xml (EX-101.LAB) — 36KB
- lixt-20240129_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 29, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan President and Chief Executive Officer -3- INDEX TO EXHIBITS Exhibit No. Description 99.1 Press release announcing the dosing of the first patient in a clinical trial for the treatment of ovarian clear cell carcinoma 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) -4-